Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617

Conclusion: A factor 3–4 lower treatment activity for 90Y-PSMA-617 translates into a comparable dosimetry estimate and clinical findings similar to those of 177Lu-PSMA-617. However, safety was demonstrated only for patients with oligometastatic disease. Further studies are needed to evaluate its potential in patients with more disseminated bone involvement or visceral metastasis.

Source: Journal of Nuclear Medicine - June 2, 2019 Category: Nuclear Medicine Authors: Rathke, H., Flechsig, P., Mier, W., Bronzel, M., Mavriopoulou, E., Hohenfellner, M., Giesel, F. L., Haberkorn, U., Kratochwil, C. Tags: Clinical Source Type: research